Subtipos del carcinoma luminal de mama según el consenso de Saint Gallen en un grupo de pacientes venezolanas

Ángel Fernández-Tortolero, Aldo Reigosa-Yániz, .

Palabras clave: adenocarcinoma, neoplasias de la mama, Venezuela

Resumen

Introducción. El cáncer de mama es la neoplasia maligna más frecuente en las mujeres de todo el mundo. Los distintos subtipos intrínsecos tienen pronósticos diferentes y su prevalencia varía significativamente según los criterios establecidos en el Consenso de Saint Gallen.
Objetivo. Clasificar los subtipos luminales del carcinoma de mama en una población de pacientes venezolanas según los consensos de Saint Gallen del 2009, 2011, 2013 y 2015.
Materiales y métodos. Se hizo un estudio retrospectivo en 209 pacientes con carcinoma ductal infiltrante de mama, atendidas en el Instituto de Oncología “Dr. Miguel Pérez Carreño” de Valencia, Venezuela.
Resultados. La distribución de los subtipos luminal A y B cambió después de reclasificar los casos según los consensos de 2011, 2013 y 2015; el subtipo luminal B fue el más común en la serie de estudio.
Conclusiones. Mediante la clasificación basada en los últimos criterios de Saint Gallen, se determinó un número mayor de tumores luminales B, lo que ayudaría a seleccionar a aquellas pacientes que no requieran la quimioterapia adyuvante y a quienes puedan beneficiarse de la terapia hormonal adyuvante en la práctica clínica.

Descargas

La descarga de datos todavía no está disponible.
  • Ángel Fernández-Tortolero Centro de Investigaciones Médicas y Biotecnológicas, Facultad de Ciencias de la Salud, Universidad de Carabobo, Valencia, Venezuela; Departamento de Ciencias Fisiológicas, Escuela de Ciencias Biomédicas y Tecnológicas, Facultad de Ciencias de la Salud, Universidad de Carabobo, Valencia, Venezuela
  • Aldo Reigosa-Yániz Centro de Investigaciones Médicas y Biotecnológicas, Facultad de Ciencias de la Salud, Universidad de Carabobo, Valencia, Venezuela

Referencias bibliográficas

Ono M, Tsuda H, Yoshida M, Shimizu C, Kinoshita T, Tamura K. Prognostic significance of progesterone receptor expression in estrogen-receptor positive, HER2-negative, nodenegative invasive breast cancer with a low Ki-67 labeling index. Clin Breast Cancer. 2017;17:41-7. https://doi.org/10.1016/j.clbc.2016.06.012

Ignatiadis M, Sotiriou C. Luminal breast cancer: From biology to treatment. Nat Rev Clin Oncol. 2013;10:494-506. https://doi.org/10.1038/nrclinonc.2013.124

Focke CM, van Diest PJ, Decker T. St Gallen 2015 subtyping of luminal breast cancers: Impact of different Ki67-based proliferation assessment methods. Breast Cancer Res Treat. 2016;159:257-63. https://doi.org/10.1007/s10549-016-3950-5

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Thresholds for therapies: Highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319-29. https://doi.org/10.1093/annonc/mdp322

Ahn HJ, Jung SJ, Kim TH, Oh MK, Yoon HK. Differences in clinical outcomes between luminal A and B type breast cancers according to the St. Gallen Consensus 2013. J Breast Cancer. 2015;18:149-59. https://doi.org/10.4048/jbc.2015.18.2.149

Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014;16:R65. https://doi.org/10.1186/bcr3679

Gao JJ, Swain SM. Luminal A breast cancer and molecular assays: A review. Oncologist. 2018;23:556-65. https://doi.org/10.1634/theoncologist.2017-0535

Fernández Á, Reigosa A, Caleiras E, Saldivia F, Hardisson D, Sanz F. Cadherins E and P expression in the molecular types of breast cancer. Invest Clin. 2015;56:155-68.

Reigosa A, Hardisson D, Sanzi F, Caleiras E, Saldivia F, Fernández A. Subclassification of the molecular types of breast cancer based on the expression of immunohistochemical markers and evolution. Invest Clin. 2016;57:187-216.

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279. https://doi.org/10.1371/journal.pmed.1000279

Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr, et al. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: Differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014;23:714-24. https://doi.org/10.1158/1055-9965.EPI-13-1023

Li AQ, Zhou SL, Li M, Xu Y, Shui RH, Yu BH, et al. Clinicopathologic characteristics of oestrogen receptor-positive/progesterone receptor-negative/Her2-negative breast cancer according to a novel definition of negative progesterone receptor status: A large population based study from China. PloS ONE. 2015;10:e0125067.

https://doi.org/10.1371/journal.pone.0125067

Caldarella A, Buzzoni C, Crocetti E, Bianchi S, Vezzosi V, Apicella P, et al. Invasive breast cancer: A significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol. 2013;139:617-23. https://doi.org/10.1007/s00432-012-1365-1

Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA. Protein expression profile and prevalence pattern of the molecular classes of breast cancer—a Saudi population based study. BMC Cancer. 2010;10:223. https://doi.org/10.1186/1471-2407-10-223

Gomez R, Ossa CA, Montoya ME, Echeverri C, Ángel G, Ascuntar J, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancermedicalscience. 2015;9:562. https://doi.org/10.3332/ecancer.2015.562

Serrano-Gómez SJ, Sanabria-Salas MC, Hernández-Suárez G, García O, Silva C, Romero A, et al. High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis. 2016;37:669-76. https://doi.org/10.1093/carcin/bgw043

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52. https://doi.org/10.1038/35021093

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-74. https://doi.org/10.1073/pnas.191367098

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-23. https://doi.org/10.1073/pnas.0932692100

Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444-55.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-50. https://doi.org/10.1093/jnci/djp082

Piccart-Gebhart MJ. New developments in hormone receptor-positive disease. Oncologist. 2011;16:40-50. https://doi.org/10.1634/theoncologist.2011-S1-40

Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: A large case series study with a longterm follow-up. Breast Cancer Res Treat. 2016;157:363-71. https://doi.org/10.1007/s10549-016-3817-9

Payne SJL, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer – the present. Histopathology. 2008;52:966-78. https://doi.org/10.1111/j.1365-2559.2007.02897.x

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502. https://doi.org/10.1001/jama.295.21.2492

Raica M, Jung I, Cîmpean AM, Suciu C, Mureşan AM. From conventional pathologic diagnosis to the molecular classification of breast carcinoma: Are we ready for the change? Rom J Morphol Embryol. 2009;50:5-13.

Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31:203-9. https://doi.org/10.1200/JCO.2012.43.4134

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptorpositive primary breast cancer. J Natl Cancer Inst. 2003;95:142-53. https://doi.org/10.1093/jnci/95.2.142

Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006;12:1013s-8s. https://doi.org/10.1158/1078-0432.CCR-05-2128

Cómo citar
1.
Fernández-Tortolero Ángel, Reigosa-Yániz A. Subtipos del carcinoma luminal de mama según el consenso de Saint Gallen en un grupo de pacientes venezolanas. biomedica [Internet]. 22 de septiembre de 2021 [citado 20 de octubre de 2021];41(3):531-40. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/5496

Más sobre este tema

Publicado
2021-09-22
Sección
Artículos originales
Crossref Cited-by logo